CD89 activation in therapy

Patent metadata

Field	Value
Publication number	US-9522184-B2
Application number	US-201113991811-A
Country	US
Kind code	B2
Filing date	Dec 14, 2011
Priority date	Dec 14, 2010
Publication date	Dec 20, 2016
Grant date	Dec 20, 2016

Abstract

The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.

First claim

The invention claimed is:

1. A method for treating an autoimmune disorder or an inflammatory condition in a patient associated with excessive neutrophil infiltration by inducing apoptosis of neutrophils, comprising:
administering to the patient having an autoimmune disorder or an inflammatory condition associated with excessive neutrophil infiltration an effective dose of a soluble CD89-activating molecule, which is a soluble Fc-alpha comprising molecule or a functional variant thereof, to bring neutrophils in contact with said molecule thereby causing apoptosis,
wherein the effective dose provides a local concentration of said soluble CD89-activating molecule at a site of excessive neutrophil infiltration which is at least about three times the IgA plasma concentration.

2. The method of claim 1 , wherein the neutrophils have been pre-activated by an inflammatory stimulus selected from the group consisting of inflammatory cytokines and microbial components.

3. The method of claim 1 , wherein the soluble CD89-activating molecule comprises Fc-alpha.

4. The method of claim 3 , wherein the soluble Fc-alpha comprising molecule is immunoglobulin A (IgA).

5. The method of claim 4 , wherein the IgA is derived from serum or plasma.

6. The method of claim 4 or 5 , wherein the IgA is dimeric.

7. The method of claim 4 or 5 , the effective dose containing an effective dose of IgA that is monomeric.

8. The method of claim 6 , wherein the IgA dimer comprises a J-chain.

9. The method of claim 8 , wherein the IgA dimer comprises a secretory component.

10. The IgA of claim 4 or 5 , wherein the IgA comprises monomeric and dimeric IgA.

11. The method of claim 4 or 5 , wherein the IgA is polyclonal.

12. The method of claim 4 , wherein the IgA is monoclonal.

13. The method claim 4 , wherein the IgA is IgA1 or IgA2or a mixture thereof.

14. The method of claim 1 , wherein the CD89-activating molecule is administered as part of a pharmaceutical composition comprising the CD89-activating molecule, wherein at least 50% of the protein in the composition is the CD89-activating molecule.

15. The method of claim 1 , wherein the neutrophils are comprised in a patient with an autoimmune disorder.

16. The method of claim 15 , wherein the autoimmune disorder or inflammatory condition is selected from sterile neutrophilic inflammation, infectious inflammation, neutrophil-induced inflammation, inflammatory bowel disease and NETosis.

17. The method of claim 15 , wherein the autoimmune disorder is arthritis.

18. The method according to claim 1 , wherein the neutrophils are in a patient with cystic fibrosis.

19. The method of claim 17 , wherein the arthritis is rheumatoid arthritis, spondyloarthritis, ankylosing spondylitis/Morbus Bechterew, or reactive arthritis.

20. A method for treating an autoimmune disorder or an inflammatory condition by inducing apoptosis of neutrophils, comprising:
administering to a patient having an autoimmune disorder or an inflammatory condition an effective dose of a soluble CD89-activating molecule, which is a soluble Fc-alpha comprising molecule or a functional variant thereof, to bring neutrophils in contact with said molecule thereby causing apoptosis, and
observing neutrophil apoptosis in the patient's neutrophils after administering the effective dose of the soluble CD89-activating molecule.

21. The method of claim 1 , wherein said effective dose is administered topically.

22. A method for treating an autoimmune disorder or an inflammatory condition in a patient associated with excessive neutrophil infiltration by inducing apoptosis of neutrophils, comprising:
administering to a patient having an autoimmune disorder or an inflammatory condition associated with excessive neutrophil infiltration an effective dose of a soluble CD89-activating molecule, which is a soluble Fc-alpha comprising molecule or a functional variant that is not IgA having a secretory component, to bring neutrophils in contact with said molecule thereby causing apoptosis,
wherein the neutrophils have been pre-activated by an inflammatory stimulus,
wherein the CD89-activating molecule is administered locally to provide the effective dose of a local concentration of said soluble CD89-activating molecule at a site of excessive neutrophil infiltration or activity which is at least about three times the IgA plasma concentration.

23. The method of claim 22 , wherein said effective dose is administered topically.

24. A method for treating an autoimmune disorder or an inflammatory condition by inducing apoptosis of neutrophils, comprising:
administering to a patient having an autoimmune disorder or an inflammatory condition an effective dose of a soluble CD89-activating molecule, which is a soluble Fc-alpha comprising molecule or a functional variant that is not IgA having a secretory component, to bring neutrophils in contact with said molecule thereby causing apoptosis,
wherein the neutrophils have been pre-activated by an inflammatory stimulus,
wherein the CD89-activating molecule is administered locally to provide the effective dose of a local concentration of said soluble CD89-activating molecule at a site of excessive neutrophil infiltration or activity which is at least about three times the IgA plasma concentration,
wherein said effective dose is administered into a diseased joint of an arthritis patient.

25. The method of claim 24 , wherein said arthritis patient is a rheumatoid arthritis patient.

26. The method of claim 22 , wherein said effective dose is administered to a site of a sterile or infectious inflammation.

27. The method of claim 22 , wherein said effective dose is administered to the site of a chronic neutrophilic inflammation.

28. The method of claim 1 , wherein said soluble CD89-activiating molecule is substantially free of secretory component.

29. The method of claim 22 , wherein said soluble CD89-activiating molecule is substantially free of secretory component.

30. The method of claim 22 , wherein said local concentration of said CD89-activiating molecule is at least about 10times the IgA plasma concentration.

31. The method of claim 22 , wherein said local concentration of said CD89-activiating molecule is at least about 20times the IgA plasma concentration.

Assignees

• Von Gunten Stephan
• Wehrli Marc
• Zürcher Adrian
• Miescher Sylvia
• Csl Behring Ag
• Univ Bern

Inventors

• Von Gunten Stephan
• Wehrli Marc
• Zürcher Adrian
• Miescher Sylvia

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title